Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Chungnam National University Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our South Korea register with Chungnam National University Hospital as lead sponsor. Synced 16 Nov 2026
12Current trials
8Recruiting now
2Drugs in these trials
1Trial register
At a glance

Chungnam National University Hospital is the lead sponsor of 12 current clinical trials in our South Korea register. 8 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are MFOLFIRINOX and MFOLFOX6. The most-studied condition is Cardiac Arrest (CA).

ClinicalTrials.gov trials by status

  • Recruiting867%
  • Active, closed217%
  • By invitation217%

Trials by phase

  • Observational867%
  • Not applicable325%
  • Phase 2/318%
01

Clinical trials sponsored by Chungnam National University Hospital

12 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Molecular Insights Into Post-Cardiac Arrest Brain Injury Via CSF Multi-Omics
NCT07481396 · ClinicalTrials.gov ↗ · Cardiac Arrest (CA), Cerebrospinal Fluid, Multiomics
Observational Recruiting 2025-12 South Korea
Self-Management Data and Disease Progression in Chronic Kidney Disease
NCT07754097 · ClinicalTrials.gov ↗ · Chronic Kidney Disease, CKD
Observational Recruiting 2026-06 South Korea
Drug Response Testing and Repurposing Using Glioblastoma Organoid
NCT06782984 · ClinicalTrials.gov ↗ · Glioblastoma, Organoid
Observational Recruiting 2021-08 South Korea
Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial
NCT06724653 · ClinicalTrials.gov ↗ · Heart Failure, Ejection Fraction, Recovery of Function
Not applicable Recruiting 2025-03 South Korea
Effect of Essential Aminoacid Supplementation and Exercise on Skeletal Muscle Function in Hemodialysis Patients
NCT05884138 · ClinicalTrials.gov ↗ · Sarcopenia
Not applicable Recruiting 2023-08 South Korea
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
NCT06519162 · ClinicalTrials.gov ↗ · Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease
Observational Recruiting 2024-07 South Korea
Analysis of Cerebrospinal Fluid Dynamics in Normal Pressure Hydrocephalus
NCT07831044 · ClinicalTrials.gov ↗ · Normal Pressure Hydrocephalus
Not applicable Recruiting 2025-09 South Korea
Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer
NCT05179889 · ClinicalTrials.gov ↗ · Colon Cancer Stage III
Phase 2/3 Recruiting 2021-07 South Korea
Efficacy and Safety of DTG/3TC in Treatment-naïve HIV-1 Infected Patients
NCT06928090 · ClinicalTrials.gov ↗ · HIV
Observational By invitation 2025-01 South Korea
Prediction of Delayed Cognitive Impairment in Cardiac Arrest Survivors With Good Neurological Outcomes
NCT05830422 · ClinicalTrials.gov ↗ · Cardiac Arrest, Out-Of-Hospital, Cognitive Impairment
Observational By invitation 2023-11 South Korea
Biliary Complication Rates in Living Donor Liver Transplantation: a Retrospective Comparative Study of Stent Versus Non-Stent Groups
NCT06767553 · ClinicalTrials.gov ↗ · Liver Failure, Living Donor Liver Transplantation, Biliary Complications
Observational Active, closed 2011-11 South Korea
Multiomics Profiling of CSF in Cardiac Arrest Survivors
NCT07090577 · ClinicalTrials.gov ↗ · Cardiac Arrest (CA), Hypoxic-Ischemic Brain Injury, Post-Resuscitation Syndrome
Observational Active, closed 2025-07 South Korea

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Chungnam National University Hospital trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Chungnam National University Hospital trials

26 conditions
Cardiac Arrest (CA)2Hypoxic-Ischemic Brain Injury2Cerebrospinal Fluid1Multiomics1Chronic Kidney Disease1CKD1Liver Failure1Living Donor Liver Transplantation1Biliary Complications1Biliary Stents1HIV1Glioblastoma1Organoid1Heart Failure1Ejection Fraction1Recovery of Function1Sarcopenia1Autoimmune Hepatitis1Primary Sclerosing Cholangitis1Non-Alcoholic Fatty Liver Disease1Liver Abscess1Normal Pressure Hydrocephalus1Post-Resuscitation Syndrome1Cardiac Arrest, Out-Of-Hospital1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in South Korea128

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Cardiac Arrest (CA)

SponsorTrials
Heartstream US1
Azienda Usl di Bologna1

Sponsors with the most current trials registered for this condition.

06

Questions about Chungnam National University Hospital trials

How many clinical trials does Chungnam National University Hospital sponsor?

Chungnam National University Hospital is the lead sponsor of 12 current trials on ClinicalTrials.gov in our South Korea register, as of the registry sync on 16 November 2026. Completed and withdrawn studies are not counted.

Are Chungnam National University Hospital trials recruiting?

Yes. 8 of its 12 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Chungnam National University Hospital testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are MFOLFIRINOX (1) and MFOLFOX6 (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 16 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.